Wells Fargo analyst Mohit Bansal maintained a Hold rating on Merck & Company yesterday and set a price target of $97.00. The company’s shares closed yesterday at $81.52. Elevate ...

New WHO guidelines endorse long-acting injectable lenacapavir for HIV prevention, Medicines Patent Pool expands licence for ...

A monthly pill would add to the growing number of choices for HIV preexposure prophylaxis, which is now seen as the best hope ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

Rahway, New Jersey Wednesday, July 16, 2025, 17:30 Hrs [IST] ...

NHS England agreed to reimburse Vertex's newest cystic fibrosis medicine. Meanwhile, Merck advanced a once-monthly PrEP pill ...

HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the initiation of the EXPrESSIVE Phase 3 ...

In a report released on July 10, Tycho Peterson from Jefferies maintained a Buy rating on Merck & Company, with a price target of $141.00. The company’s shares opened today at $83.43. Peterson covers ...

IAS 2025, the 13th IAS Conference on HIV Science, opened today with a call to accelerate access to long-acting HIV prevention and treatment innovations amid growing global funding challenges. Four ...